Literature DB >> 12007191

Defining the region(s) of deletion at 6q16-q22 in human prostate cancer.

Eija-Riitta Hyytinen1, Rega Saadut, Ceshi Chen, Lindsay Paull, Pasi A Koivisto, Robert L Vessella, Henry F Frierson, Jin-Tang Dong.   

Abstract

Deletion of the long arm of chromosome 6 (6q) frequently occurs in many neoplasms, including carcinomas of the prostate and breast and melanoma, suggesting the location of a tumor-suppressor gene or genes at 6q. At present, however, the region of deletion has not been well defined, and the target gene of deletion remains to be identified. In this study, we analyzed 44 primary prostate cancers with 16 polymorphic markers for loss of heterozygosity (LOH) by using PCR-based techniques. We also examined 23 cell lines/xenografts of prostate cancer with 38 markers for LOH by the method of homozygosity mapping of deletion. LOH at 6q16 - q22 was detected in 21 of 44 (48%) primary tumors and in 12 of 23 (52%) cell lines/xenografts. Two regions of LOH were defined. One was 7.5 cM at 6q16 - q21 between markers D6S1716 and D6S1580, and the other was 4.3 cM at 6q22 between D6S261 and D6S1702. Whereas no correlation was found between LOH at 6q16-q22 and patient age at diagnosis or Gleason score, tumors at higher stage appear to have more frequent LOH. These findings suggest that deletion of 6q16 - q22 is a frequent event in prostate cancer, and that the deletion originates from two distinct regions. These results should be useful in identifying the target gene(s) of deletion at 6q. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12007191     DOI: 10.1002/gcc.10065

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

Review 1.  Candidate genes and potential targets for therapeutics in Wilms' tumour.

Authors:  Christopher Blackmore; Max J Coppes; Aru Narendran
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

2.  A BEN-domain-containing protein associates with heterochromatin and represses transcription.

Authors:  Kizhakke M Sathyan; Zhen Shen; Vidisha Tripathi; Kannanganattu V Prasanth; Supriya G Prasanth
Journal:  J Cell Sci       Date:  2011-09-15       Impact factor: 5.285

3.  BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma.

Authors:  Christopher S Williams; Baolin Zhang; J Joshua Smith; Ashwath Jayagopal; Caitlyn W Barrett; Christopher Pino; Patricia Russ; Sai H Presley; DunFa Peng; Daniel O Rosenblatt; Frederick R Haselton; Jin-Long Yang; M Kay Washington; Xi Chen; Steven Eschrich; Timothy J Yeatman; Wael El-Rifai; R Daniel Beauchamp; Min S Chang
Journal:  J Clin Invest       Date:  2011-09-12       Impact factor: 14.808

4.  HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms.

Authors:  Can Küçük; Xiaozhou Hu; Javeed Iqbal; Philippe Gaulard; David Klinkebiel; Adam Cornish; Bhavana J Dave; Wing C Chan
Journal:  Am J Pathol       Date:  2012-11-09       Impact factor: 4.307

5.  A major lung cancer susceptibility locus maps to chromosome 6q23-25.

Authors:  J E Bailey-Wilson; C I Amos; S M Pinney; G M Petersen; M de Andrade; J S Wiest; P Fain; A G Schwartz; M You; W Franklin; C Klein; A Gazdar; H Rothschild; D Mandal; T Coons; J Slusser; J Lee; C Gaba; E Kupert; A Perez; X Zhou; D Zeng; Q Liu; Q Zhang; D Seminara; J Minna; M W Anderson
Journal:  Am J Hum Genet       Date:  2004-07-21       Impact factor: 11.025

6.  Cyclin C is a haploinsufficient tumour suppressor.

Authors:  Na Li; Anne Fassl; Joel Chick; Hiroyuki Inuzuka; Xiaoyu Li; Marc R Mansour; Lijun Liu; Haizhen Wang; Bryan King; Shavali Shaik; Alejandro Gutierrez; Alban Ordureau; Tobias Otto; Taras Kreslavsky; Lukas Baitsch; Leah Bury; Clifford A Meyer; Nan Ke; Kristin A Mulry; Michael J Kluk; Moni Roy; Sunkyu Kim; Xiaowu Zhang; Yan Geng; Agnieszka Zagozdzon; Sarah Jenkinson; Rosemary E Gale; David C Linch; Jean J Zhao; Charles G Mullighan; J Wade Harper; Jon C Aster; Iannis Aifantis; Harald von Boehmer; Steven P Gygi; Wenyi Wei; A Thomas Look; Piotr Sicinski
Journal:  Nat Cell Biol       Date:  2014-10-26       Impact factor: 28.824

7.  Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression.

Authors:  E T Goka; M E Lippman
Journal:  Oncogene       Date:  2015-02-09       Impact factor: 9.867

Review 8.  The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.

Authors:  Boris Y Shorning; Manisha S Dass; Matthew J Smalley; Helen B Pearson
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

9.  PRDM1 decreases sensitivity of human NK cells to IL2-induced cell expansion by directly repressing CD25 (IL2RA).

Authors:  Burcu Akman; Xiaozhou Hu; Xuxiang Liu; Tevfik Hatipoğlu; Hua You; Wing C Chan; Can Küçük
Journal:  J Leukoc Biol       Date:  2020-11-04       Impact factor: 4.962

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.